Weight loss jabs could help cut alcohol consumption, study suggests
It is thought the drugs help curb cravings for alcohol, experts said, although more research is needed.
Weight loss jabs, also known as GLP-1 receptor agonists, work by reducing food cravings.
The study, led by academics in Ireland and Saudi Arabia, included 262 obese people who had been prescribed liraglutide or semaglutide, which are available under the brand names Saxenda and Wegovy respectively.
They were categorised based on the amount of alcohol they consumed each week prior to starting treatment.
The groups included non-drinkers, rare drinkers who had less than 10 units a week, and regular drinkers, who reported having 10 or more units each week.
Some 188 of the 262 patients were followed up for an average of four months.
Average alcohol consumption fell from 11.3 units a week – about six or seven pints of beer – to 4.3 units a week, or roughly two pints of beer, after four months on the drugs.
Among regular drinkers, intake decreased by 68%, from 23.2 units a week to 7.8 units a week.
Professor Carel le Roux, of University College Dublin, said: 'The exact mechanism of how GLP-1 analogues reduce alcohol intake is still being investigated but it is thought to involve curbing cravings for alcohol that arise in subcortical areas of the brain that are not under conscious control.
'Thus, patients report the effects are 'effortless'.'
The findings, which are being presented at the European Congress on Obesity in Malaga, suggest a 'potential therapeutic role' for weight loss jabs in people who are obese and regularly drink alcohol, researchers said.
However, they stressed larger trials are needed to validate the results.
Prof Le Roux added: 'GLP-1 analogues have been shown treat obesity and reduce the risk of multiple obesity-related complications.
'Now, the beneficial effects beyond obesity, such as on alcohol intake, are being actively studied, with some promising results.'
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Entrepreneur
2 hours ago
- Entrepreneur
Linda Yaccarino Is a CEO Again After X Departure
The former NBC executive and X leader is now the CEO of an online GLP-1 health management company. Linda Yaccarino, the former X CEO who resigned in June, has moved on to another chief executive role. Digital health platform, eMed Population Health, which offers chronic care management related to obesity and type 2 diabetes (and access to GLP-1s), announced in a press release on Tuesday that it has appointed Yaccarino as CEO. Related: Who Is Linda Yaccarino? Everything to Know About X's Former CEO "The healthcare industry has been disrupted by technology, but not yet completely transformed by it," Yaccarino said in a statement. "There is an opportunity to combine technology, lifestyle, and data in a new powerful way through the digital channels that impact consumers directly in ways that have never been done before." In the statement, eMed says its mission is "to make safe, effective, and sustainable chronic care accessible directly through an all-in-one, digital-first experience." Yaccarino began as CEO of X in May of 2023, about six months after Elon Musk bought the company, then known as Twitter, for $44 billion. Related: 'Futures Are Intertwined': Elon Musk xAI Buys His Own Social Media Platform, X, in a $33 Billion Deal When Yaccarino publicly announced her resignation on X in June, owner Musk replied to the post with a short: "Thank you for your contributions." Before joining X in 2023, Yaccarino was the chairman of global advertising and partnerships at NBCUniversal. Join top CEOs, founders and operators at the Level Up conference to unlock strategies for scaling your business, boosting revenue and building sustainable success.
CNN
3 hours ago
- CNN
Linda Yaccarino, who just left Elon Musk's X, has a new job
Food & healthFacebookTweetLink Follow Linda Yaccarino, the former CEO of the Elon Musk-owned social media platform X, has a new leadership gig in the weight loss space. Yaccarino on Tuesday was named the CEO of eMed, a Miami-based telehealth company that dispenses GLP-1 medications such as Wegovy and Ozempic. The appointment marks a shift for Yaccarino, who has a background largely in marketing, advertising and media world. Prior to joining X, Yaccarino worked in various advertising and global partnerships for NBCUniversal and Turner for several decades. In a press release, eMed said that Yaccarino is arriving in a 'game-changing moment' in the company's five-year old history, which is to 'make safe, effective and sustainable chronic care accessible directly through an all-in-one, digital-first experience.' The company added that her experience would be 'instrumental' as it looks to accommodate more 'national and global employer and government partnerships.' 'The healthcare industry has been disrupted by technology, but not yet completely transformed by it,' Yaccarino said in a press release. 'There is an opportunity to combine technology, lifestyle, and data in a new powerful way through the digital channels that impact consumers directly in ways that have never been done before.' EMed got its start during the height of the pandemic in 2020, offering Covid tests and services. However, it has since pivoted to weight loss drugs, joining Weight Watchers, which recently exited bankruptcy and is forging a similar path of selling GLP-1 drugs online. Yaccarino didn't immediately respond to CNN's request for comment. She joined X, then called Twitter, in June 2023, which was about eight months after Musk bought the social media platform. Her main task was to help fix the platform's flagging advertising business, after the billionaire alienated brands with his controversial comments and changes to the platform. But her tenure had been marked by repeated public relations crises, including scrutiny over antisemitic and other hateful content spreading on the platform, viral false claims around international conflicts and ads that appeared alongside pro-Nazi content on the site. That led some brands to pull their spending, for which the Yaccarino-led X sued an advertising industry group — a lawsuit Yaccarino announced in a video message to all X users, in which she decried what she referred to as a conspiracy to boycott the X platform. (The industry group, Global Alliance for Responsible Media, shut down days after the lawsuit was filed.) A day before she announced her departure, the company's Grok chatbot began pushing antisemitic tropes in responses to users, however it wasn't clear that her exit was connected to that incident. The company later apologized. CNN's Clare Duffy contributed to this report.
CNN
3 hours ago
- CNN
Linda Yaccarino, who just left Elon Musk's X, has a new job
Linda Yaccarino, the former CEO of the Elon Musk-owned social media platform X, has a new leadership gig in the weight loss space. Yaccarino on Tuesday was named the CEO of eMed, a Miami-based telehealth company that dispenses GLP-1 medications such as Wegovy and Ozempic. The appointment marks a shift for Yaccarino, who has a background largely in marketing, advertising and media world. Prior to joining X, Yaccarino worked in various advertising and global partnerships for NBCUniversal and Turner for several decades. In a press release, eMed said that Yaccarino is arriving in a 'game-changing moment' in the company's five-year old history, which is to 'make safe, effective and sustainable chronic care accessible directly through an all-in-one, digital-first experience.' The company added that her experience would be 'instrumental' as it looks to accommodate more 'national and global employer and government partnerships.' 'The healthcare industry has been disrupted by technology, but not yet completely transformed by it,' Yaccarino said in a press release. 'There is an opportunity to combine technology, lifestyle, and data in a new powerful way through the digital channels that impact consumers directly in ways that have never been done before.' EMed got its start during the height of the pandemic in 2020, offering Covid tests and services. However, it has since pivoted to weight loss drugs, joining Weight Watchers, which recently exited bankruptcy and is forging a similar path of selling GLP-1 drugs online. Yaccarino didn't immediately respond to CNN's request for comment. She joined X, then called Twitter, in June 2023, which was about eight months after Musk bought the social media platform. Her main task was to help fix the platform's flagging advertising business, after the billionaire alienated brands with his controversial comments and changes to the platform. But her tenure had been marked by repeated public relations crises, including scrutiny over antisemitic and other hateful content spreading on the platform, viral false claims around international conflicts and ads that appeared alongside pro-Nazi content on the site. That led some brands to pull their spending, for which the Yaccarino-led X sued an advertising industry group — a lawsuit Yaccarino announced in a video message to all X users, in which she decried what she referred to as a conspiracy to boycott the X platform. (The industry group, Global Alliance for Responsible Media, shut down days after the lawsuit was filed.) A day before she announced her departure, the company's Grok chatbot began pushing antisemitic tropes in responses to users, however it wasn't clear that her exit was connected to that incident. The company later apologized. CNN's Clare Duffy contributed to this report.
